 This study is primarily designed to assess the safety and the tolerability of Debio1347 CH5183284 in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor FGFR 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated. 